Changsheng Bio-Technology

Changsheng Bio-Technology was a Chinese biotechnology and vaccine manufacturer headquartered in Changchun, Jilin. The company originated in 1992 as a state-owned enterprise and was converted into a family-owned private business in 2003. It developed and produced human vaccines, with rabies and diphtheria, pertussis and tetanus (DPT) vaccines among the products associated with its business. The company was listed on the Shenzhen Stock Exchange under ticker 002680.SZ. Changsheng expanded during a period in which China’s immunization system created substantial demand for domestically produced vaccines. Its reported net profit reached 566 million yuan in 2017, illustrating the scale it had achieved before its collapse. The company’s commercial position was nevertheless heavily dependent on regulatory compliance, production controls and confidence in vaccine quality. The crisis became public in 2018. Regulators found that Changchun Changsheng Life Sciences, a company unit, had falsified production and inspection data relating to a rabies vaccine. Authorities also identified problems involving DPT vaccines supplied to Shandong’s disease-control system. The affected DPT doses had been administered to 215,184 children and were found to be ineffective, although the available reference material does not establish that the doses caused illness or deaths. The findings triggered a nationwide public-health and corporate-governance scandal. The response included production suspensions, regulatory investigations, fines, executive bans and criminal proceedings. A Changsheng sales representative was also found to have paid 164,000 yuan in bribes to the head of a county disease-control center. The company was fined 3.4 million yuan in connection with the DPT matter. In October 2018, Changchun Changsheng Life Sciences was fined 9.1 billion yuan for falsifying rabies-vaccine data and producing an ineffective vaccine for babies. Four Changsheng executives were permanently barred from the securities market for information-disclosure violations, while 14 executives were prohibited from working in the pharmaceutical sector. The China Securities Regulatory Commission separately imposed a 600,000-yuan fine. The scandal severely damaged the company’s share price and destroyed its ability to operate as a vaccine manufacturer. China’s central authorities publicly condemned the conduct, and police sought the arrest of 18 people, including chairwoman Gao Junfang, on suspicion of producing and selling substandard drugs. Changsheng’s production license was revoked, the company was delisted or otherwise removed from normal public-market operation, and it subsequently entered bankruptcy proceedings. It is therefore best understood as a defunct corporate brand and a prominent case in China’s modern vaccine-regulation history rather than as an active healthcare business.

Changsheng Bio-Technology began in 1992 as a state-owned enterprise in Changchun, Jilin. Its business was centered on biotechnology and human vaccines, placing it within China’s expanding domestic pharmaceutical and immunization industry. In 2003, the enterprise became a family-owned private company. It later developed into a listed company on the Shenzhen Stock Exchange, where it traded under the code 002680.SZ. The company’s main commercial activities involved vaccine production, including rabies vaccines and DPT vaccines. Its growth was supported by demand from China’s public immunization system and by sales through disease-control and public-health procurement channels. Before its regulatory crisis, Changsheng reported net profits of 566 million yuan for 2017, indicating a substantial operating scale. The company’s position changed abruptly in 2018. Investigations found that a Changsheng subsidiary, Changchun Changsheng Life Sciences, had falsified records and data associated with rabies-vaccine production. Regulators also identified ineffective DPT vaccines supplied to the Shandong Centre for Disease Control and Prevention. Those doses had been administered to 215,184 children. The findings raised questions not only about individual batches but also about manufacturing controls, quality assurance, internal governance, sales practices and the effectiveness of regulatory oversight. The investigation broadened when authorities found that a Changsheng sales representative had paid 164,000 yuan to the head of the Changling County disease-control center. The company was fined 3.4 million yuan over the DPT issue. In October 2018, Changchun Changsheng Life Sciences received a 9.1 billion-yuan penalty for falsifying rabies-vaccine data and producing an ineffective vaccine for babies. Fourteen executives were banned from working in the pharmaceutical sector. Separately, the China Securities Regulatory Commission fined the company 600,000 yuan and permanently barred four executives from the securities market for violations of information-disclosure rules. The incident produced an unusually severe political and regulatory response. The company’s share value fell by nearly half after the data-forgery findings became public. China’s senior political leaders publicly condemned the conduct, and police planned arrests of 18 people, including chairwoman Gao Junfang, over allegations involving the production and sale of substandard drugs. Authorities revoked the company’s production license and imposed measures that made continued vaccine operations impossible. Changsheng subsequently collapsed and entered bankruptcy proceedings. The episode ended the company’s life as an operating vaccine producer and became one of the most consequential vaccine-quality scandals in China. Its history is therefore defined by two contrasting phases: an early transition from state ownership to private, listed vaccine manufacturing, followed by a rapid institutional and commercial collapse caused by quality-control failures, falsified records, alleged corruption and related disclosure violations.

1. 2018Ineffective DPT vaccines identified

   DPT vaccines supplied to Shandong were found to be ineffective after being administered to 215,184 children.

   Source
2. 2018Rabies-vaccine data falsification exposed

   Regulators found falsified production data involving a rabies vaccine made by Changchun Changsheng Life Sciences.

   Source
3. 2018Production authorization revoked and company collapsed

   Following regulatory enforcement and criminal investigations, Changsheng lost its ability to operate as a vaccine producer and later entered bankruptcy.

   Source
4. 2017Reported 566 million yuan in net profit

   Changsheng reported net profits of 566 million yuan for the year, before the following year's regulatory crisis.

   Source
5. 2003Converted to family-owned private ownership

   The company changed from state ownership to a family-owned private business.

   Source
6. 1992Established as a state-owned enterprise

   Changsheng originated as a state-owned biotechnology and vaccine enterprise in Changchun, Jilin.

   Source

A domestic Chinese vaccine producer serving the country's immunization market before its operations were ended by regulatory enforcement following the 2018 vaccine scandal.

• Rabies vaccineHuman vaccine

  A human rabies-vaccine line associated with Changsheng's vaccine manufacturing business. In 2018, regulators found falsified production and inspection data connected with a rabies vaccine made by the company's Changchun Changsheng Life Sciences unit. The findings led to production suspension, major penalties and the eventual end of the company's operations.

• DPT vaccineHuman vaccine

  Diphtheria, pertussis and tetanus vaccines supplied through China's disease-control system. Affected doses supplied to the Shandong Centre for Disease Control and Prevention were found to be ineffective and had been administered to 215,184 children. The episode became a central part of the 2018 Changsheng vaccine scandal.

• 2018Regulators revoked vaccine-production authorizationOther

  Regulators found ineffective DPT vaccines and falsified data connected with rabies-vaccine production.

  What changed. Authorities suspended the company's operations, revoked its production license and imposed penalties on the company and its executives.

  Aftermath. Changsheng could no longer operate normally as a vaccine manufacturer and subsequently entered bankruptcy proceedings.

  Source
• 2018Compensation proposed for affected peopleOther

  The vaccine-quality findings generated demands for remediation and compensation.

  What changed. Changsheng proposed compensation of between 200,000 and 650,000 yuan per person for people who had suffered from the vaccine incidents.

  Aftermath. The proposal formed part of the company's response to the public-health consequences of the scandal, while the company itself continued toward collapse.

  Proposed compensation per affected person. 200,000-650,000 yuan (2018)

  Source

• 2018Changsheng vaccine scandalControversy

  Authorities uncovered falsified rabies-vaccine production data, ineffective DPT vaccines administered to children, alleged bribery involving a sales representative, and violations of securities-disclosure rules. The investigation resulted in large fines, executive bans, criminal proceedings, revocation of production authorization and the company's eventual bankruptcy.

  Source

1. Changsheng Bio-Technology